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Introduction
More than 8 months ago (on 15 January
2008) the European Commission (“Commissi-
on“) launched a sector inquiry into the phar-
maceutical sector relating to the introduction
of innovative and generic medicines for human
consumption onto the market. The Commis-
sion believes that there are some indications
of commercial practices by pharmaceutical
undertakings intended to restrict competiti-
on in the pharmaceutical sector in the EU. In
particular, the Commission stated that less
innovative medicines reach the market and
that in some cases the entry of cheaper gene-
ric medicines seems to be delayed. "Market
monitoring suggests that these developments
result from anti-competitive practices", said
Competition Commissioner Neelie Kroes.With
the inquiry the Commission intends to take a
closer look at the commercial practices bet-
ween pharmaceutical companies, particular-
ly at patent disputes, vexatious litigation and
settlement agreements, presumably creating
artificial barriers for novel and generic medi-
cines.
What is a sector inquiry?
The Commission is entitled to open sector
inquiries relating to business sectors that do
not seem to function as well as they should,
e.g. when the trend of trade, price develop-
ments or other facts indicate that competiti-
on in a particular sector might be distorted.
The data acquired then serves as a basis for
further investigations in particular cases
against undertakings suspected of infringing
the competition law regulations. The variety
of tools to carry out a sector inquiry ranges
from simple information requests to underta-
kings and trade associations to unannounced
inspections (dawn raids).
Inquiry’s procedure
The starting signal for the inquiry into the
pharmaceutical sector apparently was the
AstraZeneca case in 2005 in which the Anglo-
Swedish pharmaceutical company was accu-
sed of misusing the patent system and the pro-
cedures for marketing pharmaceuticals to block
or delay market entry for generic competitors
to its ulcer treatment Losec. The investigati-
on resulted in a EUR 60million fine which has
been appealed by AstraZeneca.
In contrast to sector inquiries launched
before, the Commission started the inquiry
into the pharmaceutical sector with dawn raids
of a number of innovative and generic phar-
maceutical undertakings in Europe. Following
the inspections the Commission sent out detai-
led, 42-pages strong questionnaires to appro-
ximately 100 undertakings as well as to other
actors participating in the market, such as
medical organisations, associations of doctors,
pharmacies and governmental pharmaceuti-
cal price agencies. The Commission announ-
ced that it will publish an interim report on
28 November 2008 giving the market partici-
pants the opportunity to comment on the pre-
liminary results of the inquiry. The final report
can be expected in spring 2009. Depending on
the inquiry's results, the Commission or the
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national competition authorities may take
appropriate measures regarding the most
serious competition concerns.
Competition law aspects
The inquiry raises a number of questions
from the competition law point of view.
First, it has to be noticed that (the durati-
on of) any patent protection in the pharma-
ceutical sector constitutes a typical area of
conflict between the intellectual property
rights of the pharmaceutical undertakings and
the interest of the producers of generic medi-
cines in entering the market. A pharmaceuti-
cal patent grants to its holder a temporary pro-
tection from generic competition as a com-
pensation for its efforts and significant invest-
ments into the development of the novel
medicine. Taking into consideration the regu-
lar duration of a pharmaceutical patent of 20
years and the fact, that under certain circums-
tances the patent protection can be further
extended, it becomes clear that the competi-
tion on the pharmaceutical sector can be inhi-
bited in line with competition law provisions
for a quite long period of time. However, the
legal boundaries of the lawful distortion of
competition are, for instance, crossed when
an undertaking having a dominant market
position extends its patent rights by manipu-
lative or misleading practices, as the Commis-
sion was alleging in the AstraZeneca procee-
ding.
Second, the questionnaires sent by the Com-
mission bear themselves a number of risks for
the undertakings participating in the inqui-
ry. Any failure to cooperate with the Commis-
sion in a proper way can result in a separate
fine. Hence, the undertakings should treat the
questionnaires carefully and should ensure
that the information is provided in an accu-
rate manner.
Furthermore, one should bear in mind that
in their response to the questionnaires com-
panies might reveal information concerning
(unintended) anti-competitive behaviour. For
instance, a company might unveil imprudent
corporate communications which negligent-
ly were not considered to be anti-competitive
or which were not approved by the legal
department. In this case the companies could
face a separate investigation resulting in a fine
of up to 10% of the overall turnover. For this
reason especially undertakings with a signi-
ficant market power should assess the impact
of the questionnaires quite carefully.
Finally, from experience with previous
sector investigations it can be taken that the
sector inquiry will inevitably lead to a period
of legal and commercial uncertainty. Even
though the Commission stated that innovati-
on in the pharmaceutical sector is driven by
patents and other intellectual property rights
and that the inquiry will be conducted under
consideration of these existing rights, i.e. the
Commission is not willing to challenge the
existing intellectual property law system, the
final results of the inquiry will be published
at the earliest in spring 2009. Until then the
undertakings will not have the certainty that
their commercial practices are in line with the
competition law regulations as interpreted by
the Commission.
Outlook
From the present point of view it is hard to
predict which results the inquiry will have and
which conclusions the Commission will draw
from its findings. If in the course of the inqui-
ry the Commission determines that underta-
kings have infringed the competition law regu-
lations, it may impose severe fines on the
undertakings involved. It might also recom-
mend structural changes to the way the phar-
maceutical industry is functioning, as it was
the case after the inquiry into the energy
sector.
In any case, due to the vital importance of
the pharmaceutical sector for the public, the
eagerness to produce novel medicines must
not be hindered. The rigorous enforcement of
the competition law regulations is certainly
an appropriate tool towards affordable medi-
cines. However, pharmaceutical manufactu-
rers should not be discouraged from further
investments into innovative drugs!
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